1. I read with increased interest the article that is under peer-revision of
    Antonio Schuetz Antonio Schuetz Brazil says:
    May 29, 2021 at 4:16 PM

    I read with increased interest the article that is under peer-revision of Hoffmann et al., SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evade
    antibodies induced by infection and vaccination with the conclusion that B.1.617 may be able to evade control by 281 antibodies to some extension, which can be greater than detected, considering that this evaluation did not consider subtypes of SarsCov2 B1,617, specially its subtype 2…

    Reply
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback